FilingSEC EDGAR8-K
Cardiff Oncology Appoints Interim CMO and Increases Authorized Shares
· SEC accepted
StageManagement Change and Charter Amendment
Filing content
The company appointed an interim Chief Medical Officer following the resignation of the incumbent and filed an amendment to increase its authorized common stock to 300,000,000 shares.
AI summary of the filing. Please also check the source.Related companies
Analyzed by WAPE AI.
Preparing English content…
Comments —
Loading comments…